Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer
Shots:
- Under the terms of the agreement, Immutep & Merck KGaA will jointly fund the clinical trial (INSIGHT-005) whereas the Institute of Clinical Cancer Research will conduct the study as part of the INSIGHT platform that consists 5 arms from stratum A to E
- The stratum E arm, clinical trial (INSIGHT-005) is expected to evaluate the safety & efficacy of efti + avelumab in patients (n=30) with metastatic urothelial cancer with the 1st patient expected to be enrolled & dosed in H1’23 & study to be held in Germany
- Efti is a soluble LAG-3 candidate that is a first-in-class APC activator for the treatment of cancer. Additionally, efti was previously evaluated in the clinical trial (INSIGHT-004) in solid tumor patients
Ref: Globenewswire | Image: Immutep
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
